Summary Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFNa-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer. This phase II study was designed to evaluate the anti-tumour activity and toxicity of the combination of IL-2, IFNot-2a and 5-FU in patients with advanced colorectal cancer. Forty-four patients with metastatic colorectal cancer were treated, predominantly on an outpatient basis, with subcutaneous IFNa-2a and IL-2 three times per week followed by once a week bolus intravenous 5-FU injections. There were six (14%) partial responses among the 43 evaluable patients [95% confidence interval (CI) 5-28%]. Twenty-four patients had stable disease (56%) and 13 patients (30%) showed progressive disease. The median time to progressive disease in 43 patients was 19 weeks (range 2 -72 weeks) and in responders 34 weeks (range 24 -30 weeks). The median overall survival was 47 weeks (range 2 -85 weeks) and in responders 60 weeks (range 35 -71 weeks). Treatment-related toxic effects included fatigue, nausea and vomiting. Granulocytopenia was the main reason for the dose reductions or treatment interruptions in 32 out of 44 patients. One patient died of toxicity due to renal failure. Serial assessments of immunophenotyping and cytolytic activities of peripheral blood lymphocytes did not show changes in the numbers of circulating natural killer (NK) cells or in the levels of NK and lymphokine-activated killer (LAK) cytolytic activities. This regimen of IL-2 and IFNa-2a with 5-FU has only modest anti-tumour activity in advanced colorectal cancer.
The treatment of advanced and metastatic colorectal cancer remains unsatisfactory despite the availability of many cytotoxic agents. Since 1957, 5-fluorouracil (5-FU) has been the mainstay of therapy for disseminated colorectal cancer (Heidelberg, 1957) . Biochemical modulation of the effect of 5-FU with methotrexate or with leucovorin has marginally improved survival (Moertel, 1994) . Another approach appears to be the combination of 5-FU with interferonalpha (IFNcx-2a) (Wadler et al., 1989; Pazdur et al., 1990; Kemeny et al., 1990) . A potential way to improve the reported results further was suggested by Onodera et al. (1990) . They studied the effects of 5-FU + leucovorin on the interleukin 2 (IL-2)-related lymphocyte immune response. Rather than being immunosuppressive, the use of 5-FU + leucovorin appeared to augment natural killer (NK) and lymphokine-activated killer (LAK) activity. Promising clinical results were recently reported by Yang et al. (1993) applying a combination of 5-FU, leucovorin and IL-2, and by Atzpodien et al. (1994) using a combination of 5-FU, IL-2 and IFNa-2a in metastatic colorectal cancer. These studies provided the basis for the design of the study reported here with a schedule of IL-2, IFNa-2a and 5-FU in patients with advanced colorectal cancer. We used the combination of IFNa-2a and IL-2 upfront based on preclinical and clinical data suggesting synergistic anti-tumour activity of this schedule (Cameron et al., 1988; Rosenberg et al., 1989) . IFNcx can up-regulate expression of major histocompatibility class I antigens (MHC-I) on tumour cells (Weber and Rosenberg, 1988) , which are usually down-regulated when the tumour becomes more invasive (Feldman and Eisenbach, 1991; Smith et al., 1988) . IFNoc augments LAK activity (Chikhala et al., 1990) and has direct antiproliferative and cytotoxic properties against tumour cells (Gresser, 1989 WHO criteria (WHO, 1979) . Evaluation of response was performed after the second, fourth and sixth cycles. Further therapy was withheld in case of progressive disease (PD) at any time. In case of no response in the first 10 patients treated for at least 10 weeks, the trial was to be terminated. Otherwise, the sample size was to be large enough to confirm or exclude a 40% response rate by 95% confidence intervals using Pearson Clopper range limits.
Overall survival and time to disease progression were calculated from the start of treatment until the date of death or progression. The Kaplan-Meier method was used to calculate the probability of survival or time to progression.
Immunological monitoring Absolute numbers of lymphocyte subsets and cytolytic activities of peripheral blood mononuclear cells (PBMCs) were assessed immediately before and at the end of the first, second and third weeks of the first cycle, immediately before the second, third and fourth cycles (i.e. weeks 6, 10 and 14) and at the end of the fourth cycle (i.e. week 18). The PBMCs were isolated by Ficoll-Isopaque density centrifugation of 30 ml heparinised venous blood samples. An aliquot was processed immediately for immunophenotyping and the remainder was cryopreserved in liquid nitrogen to allow the cytotoxicity assays on all samples from a single patient to be tested on the same occasion, to exclude the effects of interassay variability. The lymphocyte subsets defined by CD3 and CD56, CD4 and CD8, CD16 and CD19 monoclonal antibodies were assessed by multicolour immunofluorescence and flow cytometry as described elsewhere (Gratama et al., 1996) . Cytolytic activities were determined by a standard 3 h 5'Cr-release assay as described previously (Gratama et al., 1993) . The K562 erythromyeloid leukaemia cell line and the Daudi Burkitt's lymphoma cell line were used as sources of target cells for the assessment of NK and LAK activities respectively.
Results
Patients Fifty-one patients were entered in this study between January 1991 and September 1992. Six patients were considered ineligible because they did not fulfil the inclusion criteria. One patient withdrew consent, and another patient was not evaluable for response because no post-treatment tumour assessment was available. Thus, 43 patients were evaluable for response and 44 for toxicity.
The patient characteristics are shown in Table II. Evaluation of toxicity A total of 159 treatment cycles were given, with a median of four per patient. One patient died from treatment-related renal failure. There were no other cases of drug-related renal toxicity or other grade IV toxicities. (Figure 1 ). Before therapy, the median values of the absolute numbers of NK lymphocytes (CD56+,3-; Figure la ) and cytotoxic/suppressor T lymphocytes (CD8+; Figure Id) were at the upper limit of the normal range, and the absolute number of lymphocytes (CD3+; Figure lb) was within the normal range, while that of the helper/inducer T lymphocytes (CD4+; Figure ic) was slightly below the normal range. These lymphocyte subset counts remained essentially unchanged throughout the period of treatment and shortly thereafter. Before therapy, the median NK activity of peripheral blood lymphocytes was increased (Figure le) , while LAK activity was absent in most donors ( Figure If) .
The median values of both activities increased slightly during the first therapeutic cycle to persist at those levels thereafter, al., 1988) , which appeared to be confirmed in clinical studies in melanoma and renal cancer (Rosenberg et al., 1989; Marincola et al., 1995) . The logical next step was to study the combination of the three drugs. However, we observed a meagre 14% partial response rate with a median response duration of 34 weeks. Although 78% of the patients completed at least two full courses, 32 of them (63%) required treatment interruptions or dose reductions. The most common reason for this was granulocytopenia. The majority of these dose modifications occurred during the first two courses. Hence, one could argue that the low response rate might be attributable to the moderate dose intensity achieved. Another possible reason could be the fact that 5-FU, in this study, was administered after IL-2 and IFNoc-2a, thereby not taking full advantage of the possible eradication of T-suppressor cells with chemotherapy before immunotherapy (Berendt and North, 1980) . It was also found that 5-FU cytotoxicity was enhanced by concomitant or subsequent exposure to IFNa, whereas the reverse sequence, IFNoa followed by 5-FU, abrogated the cytotoxic effect of 5-FU, suggesting that pretreatment with IFNoa could protect tumour cells (Wadler et al., 1988) . Prolonged administration of IFNa (i.e. three times a week) can induce a persistent block of tumour cells in Go-GI, thus reducing the S-phase fraction and thereby diminishing the anti-cancer activity of 5-FU (Cascinu et al., 1993) . To date, we have deliberately chosen a regimen using a loading dose of IL-2 and IFNa-2a preceding 5-FU in order to enable up-regulation of MHC-I molecules on tumour cells (Weber and Rosenberg, 1988) , to augment LAK activity (Chikhala 1990) and to exploit the antiproliferative and cytotoxic properties of IFNoc (Gresser, 1989) . However, we did not observe any changes in the tested immune parameters throughout the study. Occasionally, the lack of anti-tumour response has been associated with the development of neutralising antibodies to IL-2 and IFNoc. However, in this study two of the three patients who developed neutralising antibodies against IL-2 and IFNax-2a nevertheless achieved a partial response. As previously stated, at the time this study was designed, IFNax seemed to be an effective biomodulating agent for increasing 5-FU activity in the treatment of advanced colorectal cancer. However, recently published randomised studies have been unable to confirm this.
Hill et al. (1995a) randomised 155 patients to receive either protracted continuous intravenous infusions (c.i.v.) of 5-FU at a dose of 300 mg m-2 per day for 10 weeks in combination with IFNax-2b 5 MIU s.c. t.i.w. or c.i.v. 5-FU only. In the 5-FU/IFNa2b-group, there were significantly more episodes of mucositis (P=0.008), leucocytopenia (P=0.001), granulocytopenia (P= 0.004) and alopecia (P= 0.0002). The overall response rate in the 5-FU/IFNa-2b group was 22%, and in the 5-FU group it was 33% (P= 0.12). With a follow-up time of 861 days, the median survival in the 5-FU/IFNa-2b group was 161 days, and in the 5-FU group 193 days. The difference did not reach statistical significance. Premature withdrawals owing to toxicity in both groups of patients were equal and cannot explain the lack of IFNa-2b benefit.
The same group (Hill et al., 1995b) performed another randomised controlled phase III study in advanced colorectal cancer patients using a different dose and scheduling of 5-FU and IFNoa-2b. At the start of treatment, 106 patients received a continuous infusion of 5-FU at a dose of 750 mg m-2 per day for five consecutive days. Fifty-two patients were randomised to receive IFNa-2b at a dose of 10 MIU s.c. Likewise, in a randomised phase III study performed by the Corfu-A Study Group (1995) Despite different scheduling of IFNc and IL-2 in combination with different doses of 5-FU with or without leucovorin, all of these studies show that the addition of IFNa and IL-2 failed to improve clinical benefit over 5-FU alone. Apparently, in this case, observations from laboratory studies cannot be translated clinically.
We conclude that our schedule of IL-2 and IFNa-2a combined with 5-FU has only modest anti-tumour activity, which does not appear to be better than the expected effect of 5-FU alone. This is confirmed by randomised studies that failed to confirm the ability of IFNa and/or IL-2 to augment the efficacy of 5-FU. In our opinion, further clinical investigation of IFNoa and IL-2 in combination with 5-FU in advanced colorectal cancer is not justified.
